News room

Lyon, France – December 21, 2009

genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today reports an important framework agreement with the Tufts University (Boston, USA).

Following an international competition, the company has been selected for a framework contract for a two years renewable period.

Under the terms of the agreement, researchers at the Tufts University, whose prestigious areas of study cover oncology, cardiovascular disease and virology (especially AIDS), will benefit from the expertise gained by genOway in transgenic technologies and technological innovations developed by the company, such as inducible systems that secure and accelerate the development of sophisticated genetically modified mouse and rat models.

The financial terms of the agreement were not disclosed.

Alexandre Fraichard, CEO of genOway, declared: "We are very pleased to have signed this framework agreement with the prestigious Tufts University. This new contract adds to those signed in recent months with the most renowned U.S. universities like Pennsylvania University, Pittsburg University and the Harvard Medical School’s teaching hospital, BIDMC. The fact that these institutions, which employ some of the best scientific teams in the United States, chose our expertise and proprietary technologies makes us very proud. This improves our strong commercial dynamic and demonstrates that we offer our customers real innovations while responding to specific and diverse requests in oncology, virology, cardiovascular disease, metabolic disease or in neurosciences. And, above all, it demonstrates that these academic centers of excellence truly trust us and our work, in terms of the quality of our models, as well as our ability to meet development time objectives thanks to our efficient industrial processes."

About Tufts University
Tufts University (Boston, USA) is one of the top ten U.S. Universities according to the classification established by the Princeton Review. The excellence of its research is internationally recognized and particularly in the fields of oncology, cardiovascular disease and virology (especially AIDS). For more information please go to www.tufts.edu

Lyon, France – December 7, 2009

genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today reports an important framework agreement with Beth Israel Deaconess Medical Center (BIDMC) Harvard Medical School’s Teaching Hospital located in Boston (USA). The National Institute of Health (NIH) ranks BIDMC as the 4th best independent Teaching Hospital of the United States.

In spite of a competition with several international companies, BIDMC has finally decided to opt for genOway to conclude a framework agreement of a two years renewable period. The financial terms of the agreement were not disclosed.

With this partnership, researchers of BIDMC whose prestigious areas of study cover metabolic diseases, cardiology, neurobiology and infectious diseases including AIDS, will benefit from the expertise gained by genOway in transgenic technology and technological innovations developed by the Company, such as inducible systems that secure and accelerate the development of sophisticated genetically modified models of mice and rats.

Alexandre Fraichard, CEO of genOway, declared: "After an international competition, we have been chosen to supply BIDMC, Harvard Medical School’s prestigious Teaching Hospital with genetically modified rodents. We are very proud to provide our proprietary technologies to scientists working on such ambitious and important topics for human health such as AIDS or cancerology. For genOway, the contract takes part in the 2009 commercial dynamic that we announced in early November, after the last framework agreement established with the University of Pennsylvania (Upenn). In accordance with our goals and prospects, we continue to sign partnerships with major innovation actors that provide a solid base for our recipient economic growth in 2010 and 2011."

About BIDMC
The Beth Israel Deaconess Medical Center (BIDMC) Harvard Medical School’s Teaching Hospital is ranked according to the National Institute of Health’s (NIH) classification as the 4th best independent Teaching Hospital of the United States. It distinguishes itself with a strong overlapping of its scientific and clinical teams. BIDMC’s prestigious areas of study are metabolic disorders, neurobiology, infectious diseases, including AIDS and cardiology. More than 850 research projects are funded by agencies like the NIH or the National Science Foundation (NSF) and over 500 clinical trials of all specialties are being conducted within the center. For more information please go to www.bidmc.org

Lyon, France – November 4, 2009

genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today reports an important framework agreement with the University of Pennsylvannia (USA).

After an international competition, the company has been selected for a framework contract of a two years renewable period. Through this agreement, researchers at the University of Pennsylvania whose prestigious areas of study cover neurosciences, heart disease and metabolic disorders will benefit from the expertise gained by genOway in transgenic technology and technological innovations developed by the Company, such as inducible systems that secure and accelerate the development of sophisticated genetically modified models of mice and rats.

Financial terms of the agreement were not disclosed.

Alexandre Fraichard, CEO of genOway, declared: "We are very pleased to become, after an international competition, the supplier of the University of Pennsylvania whose research excellence is internationally renowned. Our technologies fully meet the growing needs of its academic researchers and this agreement perfectly demonstrates the very strong commercial dynamic that we encounter with academic centers. Our growth in 2010 and 2011 will come from these agreements with academic centers combined to those reached with pharmaceutical companies. We should sign before the end of the year, at least two more framework agreements with research centers of excellence and renew one of our major pharmaceutical partnership."

About The University of Pennsylvania (UPenn)
The University of Pennsylvania is a university with more than 24 000 students and more than 4 500 researchers. It contains research centers among the most efficient in the world like The Mahoney Institute of Neurological Sciences (MINS). It is considered one of the top ten U.S. Universities and has a research budget of 730 million dollars.

Lyon, France – October 20, 2009

genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today reports the signing of an exclusive license for Flex technology, developed at the Institute of Genetics and Molecular and Cellular Biology (IGBMC, Strasbourg), directed by Professor Pierre Chambon. The financial terms of the agreement were not disclosed.

This technology, combining a recombinase system with genetic modification, is the only one allowing the creation of inducible mutations. Indeed, the Flex technology enables the desired mutation to be induced in the selected target tissue at a precise moment in time. It is, therefore, an essential tool for modeling the appearance of mutations in human diseases.

Professor Pierre Chambon, said: "We are very happy to provide genOway with this license. Through its expertise and well-recognized international reputation, the company will make the best use of the Flex technology in order to model the appearance of mutations in human diseases. We believe that genOway stands out as the best partner to market this unique technology rapidly and globally."

Alexandre Fraichard, CEO of genOway, indicated: "This technology is very important for the development of even more predictive animal models. In fact, it can mimic the appearance of mutations and, therefore, help the consequences of this, for biological and pathological (or not) processes, to be understood. We are very pleased that IGBMC have granted us the exclusive rights to market this technology in animal models. We have already noticed a great deal of interest from the pharmaceutical industry for this technology and we are very confident that we will be able to sign our first contracts no later than this year. This technology represents a clear competitive advantage by strengthening our proprietary technology portfolio and increasing the uniqueness of our commercial offering."

About Professor Pierre Chambon
Pierre Chambon, honorary Professor at the College de France, is the founder and honorary director of the Institute of Genetics and Molecular and Cellular Biology (IGBMC) and Institut Clinique de la Souris (ICS) in Strasbourg-Illkirch. He has developed an internationally renowned expertise in the field of gene structure, regulation and expression, but also in the transcription of physiological signals by nuclear receptors.

About the Institute of Genetics and Molecular and Cellular Biology (IGBMC)
The Institute of Genetics and Molecular and Cellular Biology, founded in October 1994, has, since January 2001, been a joint research unit run by CNRS ,Inserm , and the Université Louis Pasteur. Directed by Pierre Chambon from 1994 to 2002, since October 2002, it has been co-managed by Dino Moras and Jean-Louis Mandel. One of the leading centers for biomedical research in Europe, it is devoted to the study of the genomes of higher eukaryotes and to the control of gene expression as well as the analysis of gene and protein functions. This knowledge is applied to the study of human diseases (cancer, monogenic diseases, metabolic diseases, etc.). It has an international reputation, emphasized by the representation of more than 40 nationalities among its researchers and students. www.igbmc.fr

Lyon, France – September 10, 2009

genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today announced its participation in the public-private AD-Inov program, selected by the Interministerial Fund (FUI) as part of its 8th call for entries.

Coordinated by Genfit, the AD-Inov program, whose budget amounts to 3.8 million EUR over 3 years, aims to develop new breakthrough technologies to support R&D and to identify new drugs that will fulfill unmet needs in Alzheimer’s disease.

According to the program, genOway’s mission is to develop new, relevant animal models to accelerate the discovery of candidate molecules exhibiting great therapeutic potential. The solutions developed should help improve the prediction of the molecules’ path through and exposure to the central nervous system under both healthy and pathological conditions.

"We are always very proud of the recognition we receive for our know-how when dealing with ambitious collaborative programs. This is the case with AD-Inov since all partners are willing to find breakthrough solutions. For genOway, it is also an opportunity to provide new services to biopharmaceutical industries active in the field of central nervous system research - including Alzheimer’s disease." said Alexandre Fraichard, CEO of genOway.

Lyon, France – May 14th 2009

genOway (ALTERNEXT-NYSE:ALGEN) reports the expansion of its business with major biopharmaceutical companies. This growing business demonstrates the quality and accuracy of genOway’s StemCellHY technology platform. The company provides customized, genetically modified rodents such as inducible and conditional knockouts, humanized models for Discovery, Preclinical, Pharmacology and DMPK departments . The main achievements of this first quarter of 2009 are

• Initial 2 Millions USD deal with a top 10 biopharmaceutical company has already been surpassed by 50% in Q1 2009. Additional business will be signed in the second quarter of 2009.
• Renewal of a 2 year master service agreement (1.2 MUSD achieved in previous agreement) with a top 10 biopharmaceutical company.

genOway’s platform is providing customers with unparalleled value in the industry:

• Shorter development times than competitors as a result of automatized production units, accurate model design and use of new stem cells lines from the StemCellHY platform
• Innovative models anticipating needs of animal models for following steps of the drug development program
• Development of models enabling better predictability of human pharmacology
• Strong customer support at each step of development: accurate project design and clear identification of risk factors, regular and detailed customer updates on the project’s development and support for model validation and readiness.

The company is expanding its portfolio of catalog models in immunology (cytokines reporter models, HLA and IgE-IgER humanized models), ADME – DMPK (CYPs, transporters) but also in metabolic disorders (ZNT8 KO and conditional KO model), pain (OPRL1 – Neuroceptin KO rat), neurosciences (SERT KO rat) and genetic tools (Cre & Flp lines).

• 4 new pharmaceutical companies are using genOway’s catalog models in this first quarter of 2009

"The growth of our biopharmaceutical business is the demonstration that our technologies are fulfilling industry expectation on both innovation and reliability. Current customer satisfaction combined with our innovative technologies and our outstanding production units is boosting our customer portfolio of pharmaceutical companies." said Alexandre Fraichard, CEO of genOway.

Lyon, France – 11 February, 2009

genOway (ALTERNEXT-NYSE EURONEXT: ALGEN; ISIN: FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, announced today the release of its new production technology StemCellHY for the creation of genetically modified models. StemCellHY has successfully passed the industrial validation and is now used in production.

The main building blocks of this production technology are:

• The bank of rodent embryonic pluripotent stem cells (ES), developed and patented by the Belgian biotech company ThromboGenics NV and now entirely the property of genOway, containing 17 lines of stem cells, embodying 67 000 samples, making it one of the densest and most valuable cell banks on the market.
• Screening automation enabling the genotyping result to be obtained in less than one day with two times less consumables.
• A proprietary technology for gene targeting, enabling the reduction by 66% of the production cost for this step.

With the implementation of this new industrialized process, genOway significantly reduces the development time of its models by 20%, allowing an average 1,5 months reduction time. This acceleration in the development of research tools gives a key advantage to genOway’s customers by speeding up their research.

Moreover, within the Stem Cell bank purchased from ThromboGenics, genOway has acquired Embryonic Stem Cells in new genetic backgrounds, which will enable the company to expand its range of animal models. The company anticipates by mid-2010 the market launch of new offerings specifically dedicated to scientists working on metabolic and inflammatory diseases, two therapeutic fields where the need for genetically modified animal models is strongly increasing.

Alexandre Fraichard, CEO of genOway, declared : "StemCellHY is a tremendous growth accelerator for genOway, allowing, at the same time, to generate significant gains in productivity and to provide the pharmaceutical industry with shorter development time. The agreement signed with ThromboGenics provides us with a key asset for this new platform, allowing us to use the most valuable Stem Cell bank. Moreover, this agreement will expand the range of models we can offer targeting key therapeutic areas like metabolic disorders."

Patrik De Haes, CEO of ThromboGenics NV, commented: "We are quite pleased to have a high technology company like genOway introduce this innovative production technology based on our Stem Cell bank. These new cell lines, developed from our internal research and offering many applications, are a valuable advance in Stem Cell technology. We consider genOway to be a natural partner for us."

About ThromboGenics
ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company’s lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.
ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at www.thrombogenics.com

Lyon, France – 13 January 2009

genOway (ALTERNEXT-NYSE:ALGEN) reports a general agreement with the Institute of Medical Microbiology (IMM) - University of Zurich. Thanks to this agreement, researchers of the Institute will benefit from genOway’s expertise in transgenesis and from innovative technologies like inducible systems that secure and speed up the creation of sophisticated genetically modified mouse models.

"Technologies developed by genOway will enable us to have access to highly innovative tools and models, which represents a key advantage in our field." said Prof. Erik C. Böttger, M.D., Director and Chairman of the Institute of Medical Microbiology.

"genOway is very proud to collaborate with the Institute of Medical Microbiology. We believe that such collaboration would be highly valuable for both partners as each brings its expertise for a common goal." said Alexandre Fraichard, CEO of genOway.

About the IMM (Institute of Medical Microbiology – Zurich)
The University of Zurich, a member of the League of European Research Universities, provides numerous academic services and research facilities, such as the functional genomics centre (www.fgcz.ethz.ch). The university collaborates with public and private sector organisations, making it an integral part of a national and global network for the acquisition and dissemination of knowledge. The Institute of Medical Microbiology (IMM) at the University of Zurich is involved in research, teaching and diagnostic services (www.imm.uzh.ch). The IMM consists of approx. 125 staff members, 95 of which are financed by the university and the remainder by research grants and outside funding. IMM promotes the continued integration among research areas involving microbiology, molecular genetics, biochemistry and cell biology, creating a highly interdisciplinary environment. The institute is fully equipped with the highest technological standards including cell biology facilities, imaging systems, molecular genetic, biochemistry and biosafety laboratories. Prof. Dr. Erik C. Böttger, Chairman and Head of the IMM, has received numerous awards including the prestigious Körber Award for European Science; he is ranked among the world’s most cited and influential microbiologists of the past two decades (isihighlycited.com).

Lyon, France 6 January 2009

genOway, (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models reports that it has filed a legal action against Cellectis S.A. and brings attention to the following details.

Indeed, to develop several genetically modified animal models and "tailor-made" models for its clients, genOway is using, among a panel of other technologies, one specific "Knock-in" homologous recombination technology. For the use of this technology, genOway, holds since 2001 a nonexclusive license agreement granted by the French company Cellectis acting in its capacity as the main licensee of Institut Pasteur, owner of the patents related to this technology. This renewable agreement falls due in September 2009.

Cellectis has recently decided to modify its sales strategy and started to contact several genOway's clients to propose them to enter directly into license agreements whereas genOway's license was precisely intended to allow it to provide its clients with a safe and fast solution where Intellectual Property was cleared up at genOway's level for any use of the model supplied by genOway in the research area -biological phenomena understanding and active substance sifting- (excluding any use of the models for production -such as recombinant proteins- or for therapeutic purposes -such as cell therapy-, working fields where genOway doesn't intervene). In this context, Cellectis also tried to terminate genOway's license before its official term and contest genOway's rights.

genOway contests firmly Cellectis' position in justice and claims several millions euros for compensation.

Despite the fact that Cellectis' technology remains relevant, it's important to underline (1) the patents filed by Cellectis in 1989 are about to become part of the public domain (March 2010) in Europe and Japan (worldwide except USA), (2) several independent technologies of genes replacement have been developed since 1989.

About the licensing agreement granted by Cellectis to genOway

The licensing agreement signed in 2001 (whose financial conditions paid by genOway were decreased in 2004) falls due in September 2009 and allows genOway's customers to use the genetically animal models in the field of pharmaceutical research: target study and compound sifting.

1.3 FIELD
One understands by "Field", the cellular system development on human culture (in vitro) and/or rodent and rodent animal models, except any other species, for the understanding of biological phenomena and/or the sifting of actives substances concerning any field excepting hormones, cytokines and human growth factor.
The use of these cellular systems on human and/or rodent and rodent animal models culture (in vitro) excepting any other species is exclusively limited for research purposes. Therefore, any use of the models for production (such as recombinant proteins) or for therapeutic use (such as cell therapy) is expressly excluded.